- SEK1.36bn
- SEK1.05bn
Brief: Flerie: Anacardio Reports Results Of Phase 1B Study Of AC01
Brief: Flerie Q3 Net Asset Value Rises To SEK 4.26 Bln
Brief: Flerie Purchased Shares In Xspray Pharma For Approx. Sek 5.6 Mln
Brief: Alligator Bioscience Appoints Johan Giléus As CFO
Brief: Flerie Explores Conditions For Directed Issue
Brief: Index Pharmaceuticals Aims To Carry Out Uplisting To Nasdaq Stockholm
Brief: Index Pharmaceuticals Says Co Has Entered Into A Conditional Agreement Regarding A Reverse Merger With Flerie
Brief: Index Pharmaceuticals Says No Dividend Shall Be Paid For Financial Year 2023.
Brief: InDex Pharmaceuticals Q1 EBIT SEK -5.3 Million
Brief: InDex Pharmaceuticals To Proceed With Reverse Merger
Brief: CEO And CFO Both To Leave Index Pharmaceuticals
Brief: Index Pharmaceuticals Says Co Will Not Proceed With Development Of Any Of Its Other Compounds
Brief: Index Pharmaceuticals Evaluates Strategic Alternatives
Brief: InDex Pharmaceuticals Q4 EBIT SEK -107.9 Million
Brief: Index Pharmaceuticals Expected Cash Balance Per March 31 SEK 180-190 Mln
Brief: InDex Pharmaceuticals Q3 EBIT SEK -42.1 Million
Brief: Index Pharmaceuticals Discontinues cobitolimod Phase III Program
Brief: Index Pharmaceuticals Gets New Patent For Cobitolimod In South Korea
Brief: Index Pharmaceuticals Granted New Patent For cobitolimod In South Korea